Literature DB >> 12519381

Development of CD4+ T cell lines that suppress an antigen-specific immune response in vivo.

L Vieira de Moraes1, B Sun, L V Rizzo.   

Abstract

It has been suggested for many years that the regulation of the immune system for the maintenance of peripheral tolerance may involve regulatory/suppressor T cells. In the past few years, several investigators have demonstrated that these cells can be generated in vitro. It has also been shown that they can inhibit the progression of various autoimmune disease models when infused into susceptible mice. We have generated two murine T cell lines in the presence of KLH-specific T cell clones from BALB/c or DBA2 mice. The lines are characterized by a low proliferative response to mitogens, the capacity to secrete high amounts of IL-10 and TGF-beta, and small amounts of IFN-gamma. Interestingly, these cells are unable to produce IL-2, IL-4 or IL-5. The study of the surface phenotype of both lines revealed CD4+, CD25high, CD44low and CTLA-4- cells. When injected intravenously in (CBy.D2) F1 mice, these cells were able to inhibit 50-100% of the TNP-specific antibody production, when the hapten was coupled to KLH. In the present study we offer another evidence for the existence of regulatory T cells in the T lymphocyte repertoire, suggesting that they can also regulate immune responses to foreign antigens. Furthermore, we demonstrate an alternative pathway to generate these cells different from approaches used thus far.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519381      PMCID: PMC1808607          DOI: 10.1046/j.1365-2249.2003.02018.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  66 in total

1.  Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment.

Authors:  O Annacker; O Burlen-Defranoux; R Pimenta-Araujo; A Cumano; A Bandeira
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

Review 2.  The third function of the thymus.

Authors:  B Seddon; D Mason
Journal:  Immunol Today       Date:  2000-02

3.  In situ immune response in gut-associated lymphoid tissue (GALT) following oral antigen in TCR-transgenic mice.

Authors:  P A Gonnella; Y Chen; J Inobe; Y Komagata; M Quartulli; H L Weiner
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

4.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

5.  Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression.

Authors:  A W Lohse; H P Dienes; K H Meyer zum Büschenfelde
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

6.  Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production.

Authors:  R A Seder; T Marth; M C Sieve; W Strober; J J Letterio; A B Roberts; B Kelsall
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

7.  CD4(+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice.

Authors:  F Van de Keere; S Tonegawa
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

8.  T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice.

Authors:  C Boitard; R Yasunami; M Dardenne; J F Bach
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

9.  Rearrangement and expression of T cell receptor genes in cloned murine natural suppressor cell lines.

Authors:  B Hertel-Wulff; T Lindsten; R Schwadron; D M Gilbert; M M Davis; S Strober
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.